Rezafungin May Offer Early Treatment Benefit Over Caspofungin In Treating Candidemia, Invasive Candidiasis, Study Finds

Infectious Disease Advisor (1/12, Kuhns) reported, “Although rezafungin and caspofungin are equally effective against all-cause mortality due to candidemia or invasive candidiasis, rezafungin might offer an early treatment benefit with its front-loaded dosing regimen.” Findings from this study were published in The Lancet Infectious Diseases.